WFDC2 and ovarian cancer: analyzed the sensitivity of CA-125 and HE4 in a cohort of 221 patients, concluding that the combined HE4 and CA-125 assay is the most effective predictor of ovarian cancer risk in patients with a pelvic mass of unknown origin (PBOT).